Black Diamond Therapeutics, a Phase 1-ready biotech developing targeted kinase inhibitors for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Cambridge, MA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol BDTX. J.P. Morgan, Jefferies and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
